Biological therapies in rheumatic diseases.

Conti, F; Ceccarelli, F; Massaro, L; Cipriano, E; Di Franco, M; Alessandri, C; Spinelli, F R; Scrivo, R

Conti, F; Ceccarelli, F; Massaro, L; Cipriano, E; Di Franco, M; Alessandri, C; Spinelli, F R; Scrivo, R.

Affiliation

Conti F; Department of Internal Medicine and Medical Specialties, Rheumatology, 'Sapienza' University, Rome, Italy.

Clin Ter ; 164(5): e413-28, 2013.

Article in En | MEDLINE | ID: mdl-24217844

Subject(s)

Biological Therapy; Rheumatic Diseases/therapy; Abatacept; Antibodies, Monoclonal/adverse effects; Antibodies, Monoclonal/immunology; Antibodies, Monoclonal/therapeutic use; Antibodies, Monoclonal, Murine-Derived/therapeutic use; B-Lymphocyte Subsets/immunology; Biological Therapy/adverse effects; Biological Therapy/statistics & numerical data; Biological Therapy/trends; Drug Therapy, Combination; Humans; Immunoconjugates/immunology; Immunoconjugates/therapeutic use; Immunoglobulin G/immunology; Immunoglobulin G/therapeutic use; Immunosuppressive Agents/administration & dosage; Immunosuppressive Agents/therapeutic use; Interferons/antagonists & inhibitors; Interleukin-1/antagonists & inhibitors; Interleukin-6/antagonists & inhibitors; Lymphocyte Depletion; Multicenter Studies as Topic; Off-Label Use; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor, Type II/antagonists & inhibitors; Rituximab; Tumor Necrosis Factor-alpha/antagonists & inhibitors

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biological Therapy / Rheumatic Diseases Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: Clin Ter Year: 2013 Type: Article Affiliation country: Italy

Fulltext

XML

PubMed Links

Search on Google